Estimation of induction and maintenance costs of infliximab, adalimumab and certolizumab pegol in managing Crohn's disease

被引：0
|
作者：
Feagan, Brian
Tan, Seng
Malone, Daniel
Hinojosa, Joaquin
Brown, Martin
机构：
[1] Robarts Res Inst, London, ON N6A 5C1, Canada
[2] UCB, Global Hlth Outcomes Res, Slough, Berks, England
[3] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA
[4] Hosp Sagunto, Gastroenterol Unit, Valencia, Spain
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2008年 / 103卷
关键词：
D O I：
10.14309/00000434-200809001-00999
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
999
引用
收藏
页码：S392 / S392
页数：1
相关论文
共 50 条
  • [11] HEALTHCARE SERVICE UTILIZATION AND COSTS OF CERTOLIZUMAB PEGOL VERSUS INFLIXIMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE
    Tkacz, Joseph
    Lee, Edward
    Low, Robert
    Stark, Jeffrey
    Yassine, Mohamed
    Brady, Brenna L.
    GASTROENTEROLOGY, 2018, 154 (01) : S22 - S22
  • [12] Certolizumab pegol in Crohn's disease
    Blick, Stephanie K. A.
    Curran, Monique P.
    BIODRUGS, 2007, 21 (03) : 195 - 201
  • [13] CERTOLIZUMAB PEGOL IN CROHN'S DISEASE
    Patel, V. K.
    Ghosh, S.
    DRUGS OF TODAY, 2008, 44 (11) : 837 - 844
  • [14] Certolizumab pegol for maintenance of medically induced remission in Crohn's disease
    Okabayashi, Shinji
    Yamazaki, Hajime
    Yamamoto, Ryohei
    Anan, Keisuke
    Matsuoka, Katsuyoshi
    Kobayashi, Taku
    Shinzaki, Shinichiro
    Honzawa, Yusuke
    Kataoka, Yuki
    Tsujimoto, Yasushi
    Watanabe, Norio
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (06):
  • [15] Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
    Vande Casteele, N.
    Feagan, B. G.
    Vermeire, S.
    Yassine, M.
    Coarse, J.
    Kosutic, G.
    Sandborn, W. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (02) : 229 - 237
  • [16] Adalimumab and Certolizumab Pegol for the Treatment of Crohn's Disease: Does BMI Make a Difference?
    Moore, John M.
    Beaulieu, Dawn B.
    Horst, Sara N.
    Armstrong, Sharelle
    Duncan, Pamela A.
    Wagnon, Julianne H.
    Duley, Caroline
    Ward, Jodie
    Rosenbury, Audra
    Schwartz, David A.
    GASTROENTEROLOGY, 2011, 140 (05) : S588 - S588
  • [17] Does Obesity Impact Treatment Efficacy of Adalimumab and Certolizumab Pegol in Crohn's Disease?
    Click, Benjamin
    Tuskey, Anne G.
    Behm, Brian W.
    GASTROENTEROLOGY, 2012, 142 (05) : S361 - S361
  • [18] Crohn's disease: certolizumab, adalimumab demonstrate efficacy in prior users of infliximab
    不详
    FORMULARY, 2007, 42 (01) : 58 - 59
  • [19] Benefit-risk assessment of the TNF-antagonists adalimumab and certolizumab pegol for maintenance treatment of Crohn's disease
    Colombel, Jean-Frederic
    Panaccione, Remo
    Robinson, Anne
    Thakkar, Roopal
    Huang, Bidan
    Pollack, Paul
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S22 - S23
  • [20] Benefit-Risk Assessment of the TNF-Antagonists Adalimumab and Certolizumab Pegol for Maintenance Treatment of Crohn's Disease
    Colombel, Jean-Frederic
    Panaccione, Remo
    Robinson, Anne
    Thakkar, Roopal
    Huang, Bidan
    Pollack, Paul F.
    GASTROENTEROLOGY, 2011, 140 (05) : S774 - S774
12345